DeCure for Megaconial type congenital muscular dystrophy
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for megaconial type congenital muscular dystrophy — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMegaconial type congenital muscular dystrophy maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for megaconial type congenital muscular dystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
choline kinase beta (CHKB) — CHKB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3LQ3 · 1.42 Å · ligand (2S)-2-[4'-({dimethyl[2-(phosphonooxy)ethyl]ammonio}acetyl)biphenyl-4-yl]-2-hydroxy-4,4-dimethylmorpholin-4-ium (HC7). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts provided do not contain any data on drug repurposing, treatment outcomes, survival rates, or response rates for megaconial type congenital muscular dystrophy. The 2010 consensus statement on congenital muscular dystrophies covers diagnosis, neurology, pulmonology, orthopedics, gastroenterology, cardiology, and palliative care, but mentions no specific drug therapy. The 2023 consensus on Duchenne muscular dystrophy discusses glucocorticosteroids and targeted pathogenetic therapies for that specific disorder, not for megaconial congenital muscular dystrophy. The 1999 book review and the 2012 and 2013 review articles describe general mechanisms, genetic heterogeneity, and diagnostic advances across muscular dystrophies, but none address megaconial type or any repurposed drug.
No evidence from these abstracts supports any drug as effective for megaconial congenital muscular dystrophy. The 2010 consensus explicitly notes that medical care for congenital muscular dystrophy remains diverse and that advances in medical technology have not been adopted in clinical practice. The 2023 Duchenne consensus states that clinical effects of new therapies depend on combination with existing standards of care, but those standards are for Duchenne, not for megaconial congenital muscular dystrophy.
What is still missing is any clinical trial data, any preclinical study of a specific compound, any patient stratification by genetic subtype, and any funding directed at drug repurposing for this specific form of congenital muscular dystrophy. Without such evidence, no conclusions about treatment can be drawn.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Cell Biology · 2013 · 234 citations · open access
Cellular and molecular mechanisms underlying muscular dystrophy
AbstractThe muscular dystrophies are a group of heterogeneous genetic diseases characterized by progressive degeneration and weakness of skeletal muscle. Since the discovery of the first muscular dystrophy gene encoding dystrophin, a large number of genes have been identified that are involved in various muscle-wasting and neuromuscular disorders. Human genetic studies complemented by animal model systems have substantially contributed to our understanding of the molecular pathomechanisms underlying muscle degeneration. Moreover, these studies have revealed distinct molecular and cellular mechanisms that link genetic mutations to diverse muscle wasting phenotypes.
Journal of Child Neurology · 2010 · 217 citations · open access
Consensus Statement on Standard of Care for Congenital Muscular Dystrophies
AbstractCongenital muscular dystrophies are a group of rare neuromuscular disorders with a wide spectrum of clinical phenotypes. Recent advances in understanding the molecular pathogenesis of congenital muscular dystrophy have enabled better diagnosis. However, medical care for patients with congenital muscular dystrophy remains very diverse. Advances in many areas of medical technology have not been adopted in clinical practice. The International Standard of Care Committee for Congenital Muscular Dystrophy was established to identify current care issues, review literature for evidence-based practice, and achieve consensus on care recommendations in 7 areas: diagnosis, neurology, pulmonology, orthopedics/rehabilitation, gastroenterology/ nutrition/speech/oral care, cardiology, and palliative care. To achieve consensus on the care recommendations, 2 separate online surveys were conducted to poll opinions from experts in the field and from congenital muscular dystrophy families. The final consensus was achieved in a 3-day workshop conducted in Brussels, Belgium, in November 2009. This consensus statement describes the care recommendations from this committee.
AbstractThe muscular dystrophies are disorders of progressive muscular degeneration and weakness. As a group they display clinical heterogeneity that reflects the heterogeneity of molecular mechanisms responsible for them, and range from congenital to adulthood onset. Recent advances in the field include improved methods of diagnosis, continued identification of disease genes, and the development of a unified model of pathogenesis in facioscapulohumeral dystrophy. These advances are reflected in the development of new therapeutic approaches, some of which have already led to clinical trials in the dystrophinopathies and limb-girdle dystrophies.
Neuromuscular Diseases · 2023 · 4 citations · open access
Consensus concept of modern effective therapy for Duchenne muscular dystrophy
AbstractDuchenne muscular dystrophy is a genetic orphan neuromuscular disease caused by a mutation in the DMD gene encoding the protein dystrophin. As a result of developing and progressive muscle damage and atrophy, children lose the ability to walk, develop respiratory and cardiac disorders. The core elements of good care standards are early diagnosis, prevention and treatment of osteoporosis, daily physical therapy, regular rehabilitation, glucocorticosteroids, and control of heart and lung function. The clinical effect of new targeted pathogenetic therapies for Duchenne muscular dystrophy, restoring synthesis of full or truncated dystrophin, depend on their appropriate combination with existing standards of care.
Journal of Neurology Neurosurgery & Psychiatry · 1999 · 0 citations · open access
Congenital Muscular Dystrophies
AbstractCongenital Muscular Dystrophies . Edited by y fukuyama, m osawa, and k saito. (Pp 432, NLG 420.00). Published by Elsevier Science, The Netherlands, 1997. ISBN 0-444-82487-1.
This book describes in detail the clinical features and latest research findings on congenital muscular dystrophy. The book follows on from an International Symposium on Congenital Muscular Dystrophies which was held in Tokyo in July 1994. The book has many positive features but also some less good features, so common in edited multiauthor texts.
On the positive side, the book gives a very comprehensive and authoritative review of the clinical features of the various types of congenital muscular dystrophies. I …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
